Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth

About this update from Super Copper Corp.

[{"type":"text","content":"Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth\n\n\n\n SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) --\n \n Cuprina Holdings (Cayman) Limited\n \n (\n \n Nasdaq: CUPR\n \n ) (“\n \n Cuprina\n \n ” or “\n \n the Company\n \n ”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced its financial results for the six months ended June 30, 2025.\n \n\n \"Although our revenue decreased and our net loss increased compared with the same period last year, the first six months of 2025 allowed us to achieve significant advances in both diversifying our product and technology portfolio and expanding our geographic footprint,” said Cuprina Chief Executive Officer, Mr. David Quek Yong Qi.\n \n\n\n Diversification and Expansion Achievements\n \n\n\n In May 2025, said Mr. Quek, the Company completed construction of, and obtained ISO 13485 certification and a dealer license for, an in-vitro fertilization (IVF) media production facility in Singapore. This facility is expected to produce IVF media product containing the nutrients, electrolytes, amino acids, and other materials required to stimulate fertilization of sperm and ovum in the lab. Cuprina plans to submit its required regulatory application to the Singapore authorities in the near future. Upon approval of this application, projected to occur by the fourth quarter of 2026, the facility is expected to commence commercial sales of this product.\n \n\n In June 2025, the Company’s indirect 49%-owned associate, Cuprina MENA Co. Ltd, completed the set-up of a laboratory in Saudi Arabia equipped to manufacture Cuprina’s MEDIFLY maggot debridement therapy (MDT) chronic wound treatment products. In July, to support Saudi Food and Drug Authority registration for these products and ISO 13485 certification for this laboratory, Cuprina engaged a local regulatory consulting firm. Upon receiving regulatory approval from Saudi authorities, the laboratory will be cleared to begin supplying these products within the Middle East and North Africa (“MENA”) region.\n \n\n The Company continued its diversification initiatives in the second half ...

More updates from Super Copper Corp.